Tetraphase to Present Research at ICAAC on Its Novel Chemistry Platform’s Ability to Address Antibiotic Resistance
- Data Will Highlight Tetraphase’s Lead Candidate, Eravacycline, as well as Additional Compounds from the Company’s Proprietary Discovery Program -
WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) announced today that nine posters and one oral presentation on data related to the Company’s next-generation antibiotics portfolio – including its lead candidate eravacycline that is currently in Phase 3 clinical development for treatment of bacterial infections including multidrug-resistant (MDR) infections – will be presented at the upcoming 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The research will highlight:
“We believe that the breadth of our 2014 ICAAC data underscores the inherent capabilities of our novel chemistry platform to produce compounds that can address numerous avenues of antibiotic resistance”
- the in-vitro activity of eravacycline against several notoriously virulent Gram-negative MDR pathogens, including Carbapenem-resistant Enterobacteriaceae;
- pre-clinical candidate TP-271’s in-vitro activity against several pathogens, including Methicillin-resistant Staphylococcus aureus (MRSA); and
- multiple hexa- and pentacycline compounds developed with the company’s proprietary chemistry platform, which have shown activity against a broad spectrum of in-vitro Gram-positive and Gram-negative bacteria.
ICAAC 2014 occurs in Washington, DC from September 5 – 9, 2014, at the Walter E. Washington Convention Center.
“We believe that the breadth of our 2014 ICAAC data underscores the inherent capabilities of our novel chemistry platform to produce compounds that can address numerous avenues of antibiotic resistance,” noted Guy Macdonald, President and CEO of Tetraphase. “We believe that this data continues to show that our drug discovery technology can become a vital component of addressing the global health crisis wrought by antibiotic resistance.”
The oral presentation, led by Tetraphase Senior Vice President of Biology Joyce Sutcliffe, Ph.D., is entitled “New Tetracyclines.” It is scheduled for Monday, September 8 from 3:30 p.m. – 4:00 p.m. ET in meeting room 202 B. Dr. Sutcliffe’s presentation will be part of the symposium “Progress on the Ribosome.”
Following are details for Tetraphase’s seven abstracts in Poster Session 172, “New Spins on Protein Synthesis Inhibitors,” which takes place on Monday, September 8, 2014, from 11:00 a.m. – 1:00 p.m. ET in Exhibit Hall B:
- “New C4-modified Tetracyclines with Broad-spectrum Activity against Gram-positive and Gram-negative Bacteria.” [F-1617]
- “7,8-Fused Pentacyclines with Promising Broad-Spectrum Antibacterial Activity.” [F-1620]
- “Novel Hexacyclic Tetracycline Analogs with Potent Antibacterial Activity against Gram-positive and Gram-negative Pathogens, including Carbapenem Resistant Enterobacteriaceae (CRE).” [F-1618]
- “Efficacy Of the Novel Fluorocycline TP-271 In A Mouse Model Of Neisseria gonorrhoeae Infection.” [F-1598]
- “TP-271, A Novel Fluorocycline, Is Efficacious in a Post-exposure Prophylaxis (PEP) Model Of Aerosolized Yersinia pestis Infection In BALB/c Mice.” [F-1599]
- “Pharmacokinetics of the Fluorocycline TP-271 in a Neutropenic Murine Lung Infection Model with Methicillin-resistant Staphylococcus aureus.” [F-1600]
- “Pharmacokinetic Evaluation of TP-271, a Novel Fluorocycline, in a Neutropenic Murine Lung Model Infected with Streptococcus Pneumoniae.” [F-1601]
Following are details for Tetraphase’s two abstracts in Poster Session 156, “Aminoglycosides and Newer Gram Negative Agents: Recent Insights,” which takes place on Monday, September 8, 2014, from 11:00 a.m. –1:00 p.m. ET in Exhibit Hall B:
- “Eravacycline Is Potent Against Third Generation Cephalosporin- And Carbapenem-resistant Enterobacteriaceae, Carbapenem-resistant Acinetobacter baumannii, And Has Isolate-specific Bactericidal Activity.” [C-1374]
- “Association between Eravacycline Activity and Efflux Expression in Strains of Acinetobacter baumannii.” [C-1375]
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multidrug-resistant (MDR) bacterial infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC). Tetraphase's lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic in the IGNITE program (Investigating Gram-negative Infections Treated with Eravacycline). Under this program, two Phase 3 clinical trials are ongoing: IGNITE 1 for the indication of complicated intra-abdominal infections (cIAI) and IGNITE 2 for complicated urinary tract infections (cUTI). Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform; in addition to eravacycline, Tetraphase has generated multiple preclinical antibiotic candidates that are currently being evaluated for clinical suitability. Please visit www.tphase.com for more company information.
Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "anticipates," "believes," "expects," "plans," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether our cash resources will be sufficient to fund our continuing operations for the period anticipated whether results obtained in preclinical studies and early clinical trials will be indicative of results obtained in future clinical trials; whether eravacycline will advance through the clinical trial process on a timely basis and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if eravacycline obtains approval, it will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of our most recent quarterly report on Form 10-Q, filed with the Securities and Exchange Commission on August 12, 2014. In addition, the forward-looking statements included in this press release represent our views as of August 21, 2014. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so.